Trial Profile
Phase Ib/II study to evaluate the efficacy and tolerability of PM01183 in combination with olaparib in patients with advanced solid tumors
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Lurbinectedin (Primary) ; Olaparib (Primary)
- Indications Breast cancer; Endometrial cancer; Ovarian cancer; Solid tumours
- Focus Adverse reactions; First in man; Therapeutic Use
- Acronyms POLA
- 01 Jun 2019 Status changed from recruiting to completed.
- 21 Jun 2017 Planned End Date changed from 1 Jul 2018 to 1 Oct 2019.
- 21 Jun 2017 Planned primary completion date changed from 1 Sep 2016 to 1 Jul 2019.